CEL-SCI Corporation (CVM)

1.4800 +0.0600 (+4.23%) 收市：04:00PM EDT

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460
https://cel-sci.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Patricia B. Prichep	Senior VP of Operations & Corporate Secretary	295.18k	無	1951
Dr. Eyal Talor Ph.D.	Chief Scientific Officer	351.88k	無	1956
Dr. Daniel H. Zimmerman Ph.D.	Senior Vice President of Research & Cellular Immunology	46.08k	無	1941
Mr. John Cipriano	Senior Vice President of Regulatory Affairs	246.97k	無	1942

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

公司管治

截至 2024年5月1日 止，CEL-SCI Corporation 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：10；董事會：10；股東權利：6；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。